The largest drug maker of country, Ranbaxy Laboratories may sell its three plants in China, Malaysia and Vietnam to mitigate the impact of global slowdown. The move is aimed rationalize company's business. It is also thinking on other cost cutting measures as per reports of confidential sources.

Ranbaxy's Chinese subsidiary, Ranbaxy Guangzhou China (RGCL) is the first ever Sino-Indian partnership across business sectors. It produces about 40 anti-infective and cardiovascular products. Malaysian and Vietnam subsideries are also leading companies in their respective areas. The company has a number of manufacturing facilities across 11 countries of world.

Ranbaxy is looking for potential buyers of plants and these could be valued at around $25-30 million. However, the company ruled out to disclose its planning. Ranbaxy CEO & MD Malvinder Singh said, "We don't comment on speculation."

It is recalled that Japan's Daiichi Sankyo has acquired 64 per cent stakes in the company and the proposed sell out of plants would be the first ever selling attempt of company's assets, after the acquisition by Japanese drug major, Daiichi Sankyo.